Document Detail


Perspectives and controversies in atrial fibrillation.
MedLine Citation:
PMID:  9737648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial fibrillation (AF) is the most common sustained arrhythmia in humans. The 3 basic tenets of therapy are (1) restoration and maintenance of sinus rhythm; (2) ventricular rate control; and (3) prevention of thromboembolism. Maintenance of sinus rhythm appears preferable to rate control alone in patients with significant symptoms caused by AF. Complete suppression of AF with drug therapy for >6 months is unusual, but it is not the sole criterion of success. As with other chronic cardiac disorders such as angina and heart failure, a marked reduction in frequency and duration of episodes of AF will likely translate into an excellent clinical outcome. The major risk of antiarrhythmic drug therapy is ventricular proarrhythmia, which is seen most frequently in patients with substantial left ventricular dysfunction. Torsade de pointes is the most frequent proarrhythmia that occurs with antiarrhythmic agents that prolong ventricular repolarization and the QT interval. To minimize the risk of proarrhythmia, antiarrhythmic drugs are started in-hospital in patients with significant heart disease, and agents are selected based on certain patient characteristics. For example, the drugs initially selected for patients with heart failure and coronary artery disease are amiodarone and sotalol, respectively. Two approaches may be used to decrease the thromboembolic risk associated with cardioversion of AF to sinus rhythm. In the conventional method, warfarin is given (INR 2.0-3.0) for 3 weeks before and at least 4 weeks after cardioversion. An alternative approach employs transesophageal echocardiography to rule out left atrial thrombi before cardioversion. Both methods appear reasonable and safe, and I prefer the conventional and transesophageal echocardiography-guided approaches for outpatients and in-hospital patients, respectively.
Authors:
E N Prystowsky
Related Documents :
2789508 - Atrial fibrillation and mortality in an elderly population.
18651488 - Electrophysiological effects of single site raa pacing evaluated by means of high-gain ...
3557988 - Design of bifunctional radiopharmaceutical for the development of 99mtc complexes for m...
16376768 - Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboem...
2492448 - Gender-related differences in cardiomyopathy.
3962858 - Incidence, timing and prognostic value of left ventricular aneurysm formation after myo...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  82     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1998 Aug 
Date Detail:
Created Date:  1998-09-17     Completed Date:  1998-09-17     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3I-6I     Citation Subset:  AIM; IM    
Affiliation:
Clinical Electrophysiology Laboratory, Northside Cardiology, St. Vincent Hospital, Indianapolis, Indiana 46260, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Atrial Fibrillation* / physiopathology,  therapy,  ultrasonography
Echocardiography, Transesophageal
Electric Countershock
Humans
Tachycardia, Sinus / physiopathology,  therapy,  ultrasonography
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholeste...
Next Document:  Measures of drug efficacy in treating atrial fibrillation.